SillaJen, Inc.
KOE: 215600.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jaekyung Kim
- Employees
- 43
- Headquarters
- Seoul, South Korea
- IPO year
- 2016
- Market cap
- ₩473.1B
- Website
- https://www.sillajen.com
Loading 215600…
Loading profile data…Frequently asked questions about 215600
What does SillaJen, Inc. (215600.KQ) do?
SillaJen, Inc. engages in the development and commercialization of oncolytic immunotherapy products. The company's lead product is Pexa-Vec, which is in Phase II clinical trial for the treatment of advanced liver cancer. It also develops JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. The company w...
Where does 215600.KQ trade?
SillaJen, Inc. (215600.KQ) trades on the KOSDAQ.
What sector is 215600.KQ in?
SillaJen, Inc. (215600.KQ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of SillaJen, Inc.?
Jaekyung Kim is the chief executive officer of SillaJen, Inc. (215600.KQ).
Where is SillaJen, Inc. headquartered?
SillaJen, Inc. is headquartered in South Korea.
Does 215600.KQ pay a dividend?
SillaJen, Inc. (215600.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 215600.KQ go public?
SillaJen, Inc. (215600.KQ) completed its initial public offering in 2016.